Goldman Sachs AM Secures $650m for Life Sciences Startup Fund

Goldman Sachs Asset Management announced a successful capital raise of $650 million for its latest venture, West Street Life Sciences I. This fund is dedicated to investing in early to mid-stage therapeutic startups within the life sciences sector, focusing on companies with multi-asset portfolios and tools and diagnostics firms. Notably, $90 million has already been committed to five promising enterprises, featuring prominent names like Nested Therapeutics, a cancer drug manufacturer, and MOMA Therapeutics, specializing in precision medicine.

This development follows Goldman's recent triumph in securing $4 billion for West Street Infrastructure Partners IV, emphasizing the firm's commitment to diverse investment opportunities across sectors. The private equity powerhouse continues to strategically position itself in the ever-evolving landscape of startup investments, showcasing its prowess in identifying and supporting promising ventures.